Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

We Can Do It Poster Male Vector Version
Pfizer's Digital Team Achieved Tough Goals Set By CEO Albert Bourla • Source: Shutterstock

Pfizer Inc. sent 90,000 people home during COVID-19 yet managed to develop its vaccine with BioNTech SE for the disease in record time. After CEO Albert Bourla credited digitalization and Project Light Speed for the achievement, senior vice-president Pfizer Digital, Robert Brown, revealed how the "secret sauce" was and continues to be used in areas ranging from response time to content management.

Talking about the digital transformation, Brown said until 2019 Pfizer had a vast digital portfolio and budget, but “we didn't...

More from Business

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?